Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.
While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.
Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.
Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.
While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.
Even as Gilead prepares to launch a third hepatitis-C product, drugs offering better antimicrobial resistance are angling for their own moments in the spotlight.
Drugmakers are working toward developing drugs in lupus, celiac disease, and other conditions that have rarely captured their attention in the past.
The bar for market success has been set high for baricitinib.
Symptom-driven care is falling out of favor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.
From hormone-replacement therapies to super-effective breast-cancer drugs to the so-called female Viagra, innovation within the women's health category has accelerated in recent months.
Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment
While advances in the treatment of hep.-C have been well noted, the infectious-diseases space has seen considerably less innovation than many other therapeutic areas. Given the stubbornness of superbugs like MRSA and growing antibiotic resistance, the healthcare industry has finally turned its attention to the category. Rebecca Mayer Knutsen outlines the potential threats and solutions
Is this finally the year that anti-obesity drugs make the leap from niche curio to mainstream therapy? Frank Celia reports on the changing practitioner mind-set that could shift odds in favor of several new weight-loss options
The rare disease drug market is making history with its steady growth and burgeoning pipeline—and owing to continuing breakthroughs in gene therapy, the biggest advances are yet to come. Rebecca Mayer Knutsen reports on a sector that is thriving—and on the possibility that issues around pricing can slow its surge.
The cardiovascular space has long ranked among the pharma industry's most vibrant. Even by that standard, however, 2015 is shaping up as a blockbuster year, and PCSK9 inhibitors have a lot to do with projections. Estimates for their success could prove even better if they are shown to reduce cardiovascular event risk, as well. Joe Dysart explains
New therapies are shaking up MS and insomnia, while the slow pace of progress in Alzheimer's continues to frustrate patients and physicians alike. Welcome to neurology, where, Joe Dysart reports, treatment breakthroughs in certain areas are counteracted by setbacks in others
The anti-vaccination movement continues to make noise, but the Ebola scare has highlighted the role vaccines play in controlling diseases—and saving lives. Joe Dysart looks at the implications of the quest for an anti-Ebola vaccine, as well as the corporate shakeup in the vaccine sector.
To see what's new in the women's health market, it might be necessary to take a look back. The return of the IUD is just one comeback shaping the future of a field that has never been a stranger to controversy. Noah Pines reports on the latest developments in this space
Immunotherapy is an emerging powerhouse in cancer treatment. Early gains being made in multiple tumor types provide a glimpse of the effectiveness of several agents and regimens. While longer follow-up is needed, the results have analysts talking about a big shift in the war on cancer. Joe Dysart reports
Gilead's curative but high-priced hepatitis C pill Sovaldi stirred payer frustration after its launch smashed sales records. Now firms from biotech to big pharma are gunning for their share of the HCV business. Will cost competition come to this space and allow these would-be rivals to chip away at Gilead's dominance? Noah Pines reports from ringside
Few autoimmune competitors even come close to commercial stalwarts Humira, Enbrel and Remicade. But as a host of high-science treatments emerge seeking to threaten their reign, an old-fashioned and heretofore illicit drug could beckon patients to look beyond traditional medicines for rheumatology relief. Joe Dysart surveys the sector
With generics firms taking aim at high-flying blockbusters, Big Pharma stalwarts in the asthma and COPD market are pinning their hopes for the future on a flurry of innovative biotech-developed assets. Noah Pines charts the rarefied air of the respiratory space